Europe Radioimmunoassay Market Discussed in New MicroMarketMonitor Report Now Available at MarketPublishers.com19 Oct 2015 • by Natalie Aster
LONDON – The technique of radioimmunoassay (RIA) is advanced and sensitive enough to find small molecules in the blood, and is therefore used for research purposes and diagnosis of diseases, such as cancer. This technique is also implemented by organizations and research labs for research purposes using serum from animals or humans. The new range of immunoassay kits and analyzers provide remedies for autoimmune diseases, such as diabetes. These are widely used in the process of drug discovery and screening in blood banks.
Radioimmunoassay (RIA) is one of the pivotal and traditional methods used for the testing of endocrinological disorders. RIA also has prominent usage in the field of neurodegenerative disorders. In spite of the high precision, robust nature, and impeccable sensitivity, the global radioimmunoassay (RIA) market has been witnessing a slow growth in terms of market values and kit volumes. This can be attributed to the paradigm shift in the adoption of alternatives, such as, ELISA, chemiluminescence assay, immunofluorescence assay, & other non-radio techniques and lack of automation.
In Europe, many clinical laboratories are taking measures to remove RIA tests off their shelf; ELISA has been instrumental in taking over the RIA tests. European Greens has been instrumental in maintaining environmental responsibility across geographies. The utilization of radioactive substances in RIA procedures poses a threat to environment and human health. Thus, the political scenario has negatively impacted the use of RIA tests in Europe due to the conscious effort from the European Greens. In spite of the above-mentioned dynamics, Europe captures a major market share in RIA globally. Majority of the RIA manufacturers are based out of Europe, thus claiming a strong footprint in Europe.
The major players in the radioimmunoassay are IBL International (A Tecan Company) (Germany), Cisbio (France), DiaSorin S.p.A. (Italy), Izotop (Hungary), Berthold Technologies GmbH & Co. KG (Germany), and Stratec Biomedical AG (Germany), Euro Diagnostica AB (Sweden), DIAsource ImmunoAssays SA (Belgium), PerkinElmer, Inc. (U.S.), MP Biomedicals, LLC (U.S.), DRG International, Inc. (U.S.), & Beckman Coulter, Inc. (U.S.).
New research study “Europe Radioimmunoassay Market By Type (Reagents & Kits, Analyzers), by Application (Research, Clinical Diagnostics), by End User (Hospital, Pharmaceuticals Industry & CRO, Academics, Clinical Diagnostic Laboratories, Others), & By Geography-Analysis & Forecast to 2020” prepared by MicroMarketMonitor offers an insightful analysis of the European radioimmunoassay (RIA) market, segmenting it based on type, end-user, application, and by geography; presenting exhaustive value analysis for 2014 and also forecasts through to 2020.
It presents an in-depth market share analysis, by revenue, of the leading companies.
In addition, the report also profiled key players of the market on various parameters such as business overview, financial overview, product portfolio, business strategies and recent developments of the respective company.
Europe Radioimmunoassay Market By Type (Reagents & Kits, Analyzers), by Application (Research, Clinical Diagnostics), by End User (Hospital, Pharmaceuticals Industry & CRO, Academics, Clinical Diagnostic Laboratories, Others), & By Geography-Analysis & Forecast to 2020
Published: October, 2015
Price: US$ 2,650.00
More new reports by the publisher can be found at MicroMarketMonitor page.